BIOIO validates its in silico Gene2Drug MOAT module in models of Rheumatoid arthritis. MOAT identified a chemical mimic of IKBz inhibition (Pubmed: 39279148).

BIOIO adds Ildiko Lingvay, MD, a pioneering clinical trialist for the GLP-1 RAs and Professor at Univ. of Texas Southwestern to its Scientific Advisory Board.

Missouri Technology Corporation, a for-profit public private partnership awarded BIOIO seed funding in its January 2024 investment cycle.

BIOIO and LabDAO form partnership to virtualize drug discovery.

BIOIO-2001 was funded by VitaDAO using Molecule’s IP-NFT framework.

BIOIO posts BIOIO-1001 manuscript to BioRxiv.